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Tolvaptan and related V2-specific vasopressin receptor
antagonists have been shown to delay disease progression in
animal models of polycystic kidney disease. Slight elevations
in serum creatinine, rapidly reversible after drug cessation,
have been found in clinical trials involving tolvaptan. Here,
we sought to clarify the potential renal mechanisms to see
whether the antagonist effects were dependent on
underlying renal function in 20 patients with Autosomal
Dominant Polycystic Kidney Disease (ADPKD) before and
after 1 week of daily split-dose treatment. Tolvaptan induced
aquaresis (excretion of solute-free water) and a significant
reduction in glomerular filtration rate (GFR). The serum uric
acid increased because of a decreased uric acid clearance, and
the serum potassium fell, but there was no significant change
in renal blood flow as measured by para-aminohippurate
clearance or magnetic resonance imaging (MRI). No
correlation was found between baseline GFR, measured by
iothalmate clearance, and percent change in GFR induced by
tolvaptan. Blinded post hoc analysis of renal MRIs showed that
tolvaptan significantly reduced total kidney volume by 3.1%
and individual cyst volume by 1.6%. Preliminary analysis of
this small cohort suggested that these effects were more
noticeable in patients with preserved renal function and with
larger cysts. No correlation was found between changes of
total kidney volume and body weight or estimated body
water. Thus, functional and structural effects of tolvaptan on
patients with ADPKD are likely due to inhibition of V2-driven
adenosine cyclic 30,50-monophosphate generation and its
aquaretic, hemodynamic, and anti-secretory actions.
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Tolvaptan is an orally effective, non-peptide arginine
vasopressin (AVP) V2 receptor antagonist currently approved
in the United States and EU for the treatment of
hyponatremia associated in euvolemic and hypervolemic
states and SIADH, respectively, and in Japan for the treatment
of cardiac edema resistant to diuretics. Tolvaptan is also being
studied as an adjunct therapy for volume overload in patients
with heart failure and as a primary therapy to delay
progression of Autosomal Dominant Polycystic Kidney
Disease (ADPKD). Both tolvaptan and a related V2-specific
AVP receptor antagonist have been shown to delay disease
progression in animal models of human polycystic kidney
disease.1–3 The mechanism of these effects is proposed to
involve inhibition of the AVP V2 receptor and the subsequent
decrease in adenosine cyclic 30,50-monophosphate concentra-
tions in the kidney. Elevated adenosine cyclic 30,50-mono-
phosphate in the kidney is thought to promote cyst fluid
accumulation and the epithelial cell growth, thereby displa-
cing normal kidney and accelerating renal failure.4,5
Transient decreases in blood urea nitrogen and increases in
serum creatinine and uric acid have been observed during
tolvaptan’s evaluation for indications involving patients with
hyponatremia and heart failure.6,7 In these studies, the incidence
of adverse events related to acute or chronic renal failure have
been similar, but consistently numerically lower in those treated
with tolvaptan than with placebo. Similar changes have been
seen in ADPKD patients who have been given twice-daily
tolvaptan (to consistently inhibit AVP action at the kidney’s
AVP V2 receptors) over the last 4 years in an open-label study.
8
Because renal function is critically important to those
diagnosed with ADPKD, we sought to clarify the possible
mechanisms of these changes in serum creatinine by studying
renal hemodynamics and function in ADPKD patients given
daily, split-dose tolvaptan administration over 1 week. We
also sought to determine whether the level of residual renal
function impacts the effect of tolvaptan on glomerular
filtration rate (GFR) and creatinine clearance. Analysis of
renal structure, along with correlations to hemodynamics
and function were added post hoc.
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RESULTS
Baseline clinical and laboratory parameters and kidney
volumes
The baseline (day 0) clinical and laboratory parameters are
shown in Table 1. Baseline total kidney volume (TKV) was
inversely correlated with baseline para-aminohippurate
(PAH)-renal blood flow (RBF) (and, not shown, magnetic
resonance (MR)-RBF) and GFR, and directly correlated with
urine albumin excretion (Figure 1a–c). PAH- and MR-RBFs
were highly correlated (r¼ 0.958, Po0.001), but the ratio of
PAH-RBF to MR-RBF was lower in the patients with a GFR
o60ml/min per 1.73m2 possibly because the 90% renal
extraction of PAH used to estimate RBF-PAH is too high
when renal function is low (results not shown).
Short-term effects of tolvaptan on clinical and laboratory
parameters and kidney volumes
As expected the administration of tolvaptan induced
aquaresis, which was accompanied by reductions in body
weight of 1.6% and increases in plasma sodium concentra-
tion of 1.1% (Table 1). Estimated total body water decreased
by 1.1% (not shown). No significant changes were observed
in blood pressure, hematocrit or serum protein, and albumin
concentrations (Table 1).
Serum creatinine, cystatin C, and uric acid increased by
8.9, 8.9, and 13.0% (Table 1), respectively. The percent
increase in serum uric acid was numerically greater than
creatinine or cystatin C but not significantly so (P¼ 0.16 and
0.30). Serum blood urea nitrogen and plasma renin activity
and aldosterone did not change significantly (not shown).
The administration of tolvaptan increased urine flow and
free water clearance, and induced an 8.6% reduction in GFR,
without a consistent or significant change in RBF-PAH or
RBF-magnetic resonance imaging (MRI; Table 1). There was
no correlation between percent changes in GFR and GFR
values at baseline (P¼ 0.398). Consistent with its effect on
GFR, tolvaptan significantly reduced the osmolar and uric
acid clearances, but only the reduction in uric acid clearance
remained significant when these clearances were adjusted for
the reduction in GFR (Table 1). Moreover, the percent
reduction in uric acid clearance was significantly larger than
the reduction in GFR, indicating that a change in the rates of
uric acid reabsorption and/or secretion contributes to the
reduction in uric acid clearance in addition to the reduction
in GFR.
Changes in TKV were not an initial focus for this study, as
it had been believed that it would take months to detect the
effects due to inhibition of cell proliferation or fluid
secretion. Unexpectedly, however, a post hoc-blinded analysis
of the renal MRI obtained for measurement of renal blood
flow and to document disease progression showed a 3.1%
reduction in TKV from baseline after 1 week of tolvaptan
therapy (Po0.001; Table 1, Figure 2). The percent change in
right and left kidney volumes were significantly correlated
Table 1 | Short-term effects of tolvaptan on clinical and laboratory parameters and on TKVs
All study participants
Pre Post %W P-value
Age (years) 47.8±8.7
Weight (kg) 84.0±22.0 82.7±21.7 1.6±1.3 o0.001
MAP (mmHg) 92.0±10.1 90.0±10.8 1.7±10.1 0.390
RKV (ml) 1236±1538 1211±1533 4.0±4.1 o0.001
LKV (ml) 1081±1211 1064±1201 2.5±2.9 0.003
TKV (ml) 2316±2715 2274±2700 3.1±3.0 o0.001
Hb (g/dl) 13.0±1.1 13.0±1.0 0.1±5.4 0.925
Protein (g/dl) 7.0±0.6 7.1±0.4 2.8±7.8 0.153
Albumin (mg/l) 4.4±0.2 4.4±0.3 0.9±4.1 0.323
GFR (ml/min per 1.73m2) 69.3±34.8 62.4±28.7 8.6±13.9 0.018
PAH (ml/min per 1.73m2) 345.7±184.4 320.5±156.7 5.7±13.1 0.071
RBF-PAH (ml/min per 1.73m2) 619±338 570±286 5.9±15.6 0.109
RBF-MRI (ml/min per 1.73m2) 536±266 514±221 1.0±18.9 0.459
SCr (mg/dl) 1.4±0.8 1.5±0.8 8.9±10.5 0.004
Cystatin C (mg/l) 1.2±0.6 1.3±0.6 8.9±10.4 0.011
BUN (mg/dl) 21.7±10.7 21.1±10.0 1.3±16.4 0.564
Uric acid (mg/dl) 5.6±2.1 6.2±2.2 13.0±14.1 0.002
Sodium (mmol/l) 137.9±2.3 139.5±2.7 1.1±1.2 o0.001
Potassium (mmol/l) 4.6±0.5 4.4±0.6 4.8±5.5 0.001
Urine flow (ml/min) 7.3±3.2 8.5±3.1 23.8±43.9 0.012
CH2O (ml/min) 4.1±2.7 6.0±2.8 91.7±160.7 o0.001
(CH2O/GFR) 100 5.6±2.7 9.1±2.2 107±131 o0.001
Cosm (ml/min) 3.3±0.8 2.7±0.8 16.0±16.9 0.001
(Cosm/GFR) 100 5.1±2.2 4.8±2.2 6.6±16.7 0.121
Curi (ml/min) 9.6±4.9 6.8±3.0 26.8±14.8 o0.001
(Curi/GFR) 100 12.8±3.6 10.6±4.5 18.7±17.2 o0.001
Abbreviations: BUN, blood urea nitrogen; CH2O, free water clearance; Cosm, osmolar clearance; Curi, uric acid clearance; GFR, glomerular filtration rate determined by
iothalamate clearance; Hb, serum hemoglobin; LKV, left kidney volume; MAP, mean arterial pressure; PAH, para-aminohippurate clearance; RKV, right kidney volume; RBF-
PAH, renal blood flow determined by para-aminohippurate clearance; RBF-MRI, renal blood flow determined by magnetic resonance imaging; SCr, serum creatinine; TKV,
total kidney volume.
Bold denotes statistical significance.
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(r¼ 0.526, P¼ 0.017). No significant correlation was detected
between the changes in TKV and body weight (r¼ 0.054, NS)
or estimated body water (r¼ 0.184, NS; not shown). The
percent reduction in TKV was higher in patients with a GFR
X60ml/min per 1.73m2 than in those with a GFR o60ml/
min per 1.73m2, without reaching statistical significance
(P¼ 0.057).
To determine whether the reduction in kidney volume was
due to changes in cyst volume, we measured individual cyst
volumes in nine patients (six with a GFR X60ml/min per
1.73m2 and three with a GFR o60ml/min per 1.73m2). A
total of 11–20 cysts per patient were measured before and
after the administration of tolvaptan. To protect against bias
the two MRIs for each patient were de-identified and dates of
examinations removed, so that the examiner was blinded to
the dates and patient data. The two MRI studies for each
patient, however, were examined at the same time. Excellent
image quality in both studies was used as the criterion to
otherwise randomly select 11–20 cysts from each patient
between 10 and 100mm in diameter to measure individual
cyst volumes. In eight of the nine patients, the mean cyst
volume was lower following the administration of tolvaptan
and in three of them the change was statistically significant.
The overall percent reduction in individual cyst volume was
1.64% (P¼ 0.0004). The percent reduction of individual cyst
volumes was more marked in patients with a GFR X60ml/
min per 1.73m2 than in those with a GFR o60ml/min per
1.73m2 (Figure 3a). The percent reduction in cyst volume
associated with the administration of tolvaptan was sig-
nificant in cysts X10ml, but not in those o10ml (Figure
3a). Percent changes in individual cyst volumes were
correlated with natural log transformed cyst volumes at
baseline (P¼ 0.002; Figure 3b).
Safety of short-term administration of tolvaptan
The administration of tolvaptan was well tolerated and all the
patients completed the study without discontinuation of the
medication. Common adverse events included polyuria
(100%), polydipsia (100%), nocturia (85%), and dry mouth
(45%). There were no serious adverse events.
DISCUSSION
The main observations of this study are that the adminis-
tration of tolvaptan over 1 week reduces GFR and
significantly reduces kidney and cyst volume to a greater
extent than it reduces body weight and body water.
The reduction in GFR induced by tolvaptan occurred
without a significant change in RBF measured indirectly by
the PAH clearance or directly using MRI. Nevertheless,
reductions in PAH clearance and PAH-RBF approached
statistical significance, and an effect of tolvaptan on PAH
clearance and RBF cannot be excluded because of the small
sample size. We cannot exclude either that a reduction in
filtered PAH or an interference of tolvaptan or one of its
metabolites with the tubular secretion of PAH could account
for these trends. The MR results suggest that the adminis-
tration of tolvaptan does not have an effect on RBF or
that this effect is small and not likely to explain the reduction
in GFR.
As previously observed in patients with ADPKD, admin-
istration of this drug acutely results in a small increase in
serum creatinine concentration, which is paralleled by a
similar reduction in GFR. The percent reduction in GFR is
similar in patients with chronic kidney disease stage 1 or 2
and in those with chronic kidney disease stage 3. It is unlikely
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that the observed 1.1% reduction in total body water
accounts for the 8.9% increase in serum creatinine. More-
over, an increase in serum creatinine by this mechanism
should be self-limiting, as it would result in an increase in
filtered creatinine and creatinine clearance. It is also unlikely
that relative contraction of plasma volume accounts for the
8.6% reduction in GFR, as no significant change in blood
hemoglobin or serum protein or albumin concentration was
detected and GFR is usually maintained in the presence of
moderate volume contraction by efferent arteriolar constric-
tion and an increase in glomerular pressure.9
As the administration of tolvaptan results in an increase in
vasopressin release, the possibility that a higher level of
circulating vasopressin accounts for the reduction in GFR has
to be considered.10 Direct hemodynamic effects of vasopres-
sin on V1a receptors in the renal vasculature are not likely to
account for the observed change. Under physiological
conditions, elevations of circulating vasopressin within the
physiological range induced by water restriction or exogen-
ous administration have no effect on RBF or GFR.11–13 A
renal vasoconstrictor response to vasopressin is observed only
with very high concentrations of vasopressin.14 Increased
levels of circulating vasopressin are more likely to have
an effect on the efferent arterioles and medullary circula-
tion,15–20 but this would increase rather than decrease GFR.
Although direct effects of vasopressin on the renal
vasculature are unlikely explanations for the observed
changes, a direct effect of circulating vasopressin on
glomerular function may contribute to the reduction in
GFR. Administration of vasopressin to rats undergoing water
diuresis induces a marked decline in hydraulic pressure
within the Bowman’s space, but GFR remains unchanged
because the increase in pressure gradient is offset by a
reduction in the glomerular ultrafiltration coefficient,
possibly due to a direct effect on mesangial V1a receptors
and mesangial cell contraction.21,22
Tolvaptan may also lower GFR by inhibiting the
vasopressin V2-mediated urine concentrating activity
and indirectly affecting renal hemodynamics.23,24 Urine
osmolality and GFR were found to be directly correlated in
conscious rats when urine concentrating activity was
increased by a constant infusion of 1-deamino-8-D-arginine
vasopressin or reduced by increasing water intake. Reducing
AVP V2R activity may reduce GFR through reduction of urea
recycling and/or sodium chloride reabsorption in the thick
ascending Henle’s limb, lowering the sodium concentration at
the macula densa and suppressing tubuloglomerular feedback.
Urine concentrating activity and GFR are also correlated in
healthy human volunteers during low and high hydration.25
AVP administration to water loaded healthy volunteers induces
parallel increases in creatinine clearance and urine osmolality.26
Conversely, administration of V2R antagonists after dehydration
induces a fall in creatinine clearance.
The other main observation of this study is that
administration of tolvaptan for 1 week is sufficient to induce
a significant reduction in TKV and volume of individual
cysts. It seems unlikely that the 1.1% reduction in total body
water entirely accounts for the 3.1% reduction in TKV. The
lack of correlation between the percent changes in total body
water (or body weight) and in total kidney weight supports
this interpretation. A plausible explanation for the tolvaptan
induced reduction in kidney and cyst volumes in this study is
consistent with its proposed mechanism of action in
polycystic kidneys, that is, inhibition of adenosine cyclic
30,50-monophosphate production and chloride-driven fluid
secretion.1–5 Indeed, renal cysts excised from patients with
ADPKD secrete as well as absorb fluid in vitro and the rate of
net fluid secretion is augmented by forskolin, which activates
adenylate cyclase.27 Moreover, tolvaptan inhibits AVP-in-
duced chloride currents in ADPKD cell polarized monolayers
and AVP-induced growth of ADPKD cell-derived microcysts
in collagen gels.28 Therefore, inhibition of fluid secretion by
tolvaptan may alter the balance between secretion and
absorption, and induce net fluid reabsorption and reduction
in cyst volume. The greater effects of tolvaptan on kidney and
cyst volumes in patients with a GFRX60ml/min per 1.73m2
suggest that tolvaptan may be more effective in early than in
late stages of the disease. Given the small sample size,
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however, these comparisons should be regarded as explora-
tory and hypothesis generating. Confirmation of these
specific hypotheses will necessitate a replicate study in which
the proposed hypothesis is stated as primary or secondary
with appropriate adjustment to exclude type I error.
A few other observations merit comment. Administration
of tolvaptan resulted in a reduction in uric acid clearance and
an increase in serum uric acid levels that were more marked
than changes in GFR and levels of serum creatinine and
cystatin C. An elevation in serum uric acid is a characteristic
of both central and nephrogenic diabetes insipidus.29,30 It has
been suggested that the degree of the elevation may be more
marked in central than in nephrogenic diabetes insipidus
because stimulation of V1a receptors may have a uricosuric
effect.29 Changes in uric acid clearance often closely correlate
with changes in RBF. In our study, however, the reduction in
uric acid clearance occurred in the absence of a significant
change in RBF, particularly when we consider the RBF-MRI,
which likely is more reliable than RBF-PAH in patients
with impaired renal function. The reduced renal clearance
of uric acid associated with the administration of tolvaptan
may be linked to increased proximal reabsorption of
sodium to compensate for reduced V2 receptor-mediated
sodium reabsorption in the distal nephron and collecting
duct.31–34 An additional finding associated with the admin-
istration of tolvaptan is a small but significant reduction in
the level of serum potassium. This may be due to the
increased rate of sodium and fluid delivery to the cortical
collecting duct.35
In summary, the results of this study suggest that, very
early after initiation of treatment with tolvaptan, there is an
increase in serum creatinine because of a reduction in GFR
likely due to its effects on tubuloglomerular feedback and/or
glomerular ultrafiltration, a reduction in TKV and cyst
volume accounted at least in part by its effects on fluid
secretion, and a serum uric acid increase and potassium
decrease likely explained by its effects on sodium reabsorp-
tion in the distal nephron and collecting duct.
MATERIALS AND METHODS
Study subjects
Study participants were previously diagnosed ADPKD patients
based on Ravine’s criteria,36,37 18–60 years of age, and selected to
represent a wide range of disease severity with estimated creatinine
clearances by the Cockcroft–Gault equation X30ml/min. A total of
20 participants (10 caucasian males and 10 caucasian females) were
enrolled in the study, in which 12 had eCrClX60ml/min (6 without
hypertension and 6 hypertensive) and 8 had eCrCl 30–59ml/min (all
hypertensive). Exclusion criteria included concurrent diseases that
could interfere with the conduct of the study or the interpretation of
the results (for example, diabetes mellitus), uncontrolled hyperten-
sion, use of diuretics, administration of an investigative drug or
donation of blood within 30 days before dosing, allergy to iodine
or benzazepines, and contraindications to MR studies. The
antihypertensive regimen for the study participants with hyperten-
sion included an angiotensin I converting enzyme inhibitor or an
angiotensin II receptor blocker. The protocol was approved by the
Mayo Institutional Review Board. Written informed consent was
obtained from all patients.
Study design
This is a single center, sequential, multiple-dose study of the effect of
a split-dose regimen of tolvaptan tablets on renal function in
patients with ADPKD. Subjects checked into the outpatient clinic on
day 1 and underwent physical examination and measurements of
serum chemistry and hematology parameters, urinalysis, and if
applicable exclusion of pregnancy. On study day 0, all subjects
underwent baseline renal function testing. Subjects were given
enough study medication for 7 days and were instructed to
administer tolvaptan in a split-dose regimen, 45mg (3 15mg,
oral tablets) on awakening followed by 15mg (1 15mg, oral
tablet) 8 h later on study days 1–6. On day 7, subjects administered
tolvaptan 45mg (3 15mg) on awaking at home and the 15mg
dose was administered in the study facility B8 h after the morning
dose. On study day 8, subjects were given the 45mg dose at 0700
hours in the study facility and underwent measurements of renal
clearances, followed by measurements of RBF by MRI, and
chemistry and hematology parameters.
Laboratory measurements of renal clearances, RBF, and total
body water
On days 0 and 8, subjects were instructed to wake up at 0600 hours,
remain upright for 2 h. They reported to the Renal Function
Laboratory at 0645 hours at which time height and weight were
obtained and an intravenous needle for blood collection was placed
in the dominant arm. At 0700 hours, they drank 240ml of water
(day 0) or took 45mg of tolvaptan with 240ml of water (day 8).
Between 0700 and 0800 hours they drank 720–1200ml of water. At
0800 hours, blood and urine samples were collected for plasma
aldosterone, serum cystatin C, standing plasma renin activity, and
predose iothalamate and PAH. An intravenous catheter was inserted
into the non-dominant arm to administer the priming and
sustaining solutions of iothalamate and PAH. Blood and urine
samples were collected within 5min of each other every 30min
between 0900 and 1030 hours for measurements of iothalamate,
PAH, urea, creatinine, uric acid, osmolality, urinary protein, and
albumin. Bladder emptying was monitored by ultrasound. GFR
and renal plasma flow (RPF) were determined by iothalamate
and PAH clearances, respectively. Clearances were calculated as
UiV/Pi and UPAHV/PPAH 1.1 and the average of the three
collection intervals were considered the final value of the renal
function test. RBF was estimated from RPF values obtained from
clearance of PAH using the measured hematocrit values as
RBF¼RPF/(1hematocrit).
Race- and sex-specific total body water (TBW) prediction
equations38 were used to estimate TBW at baseline. TBW on day 8
was estimated as the baseline TBW minus free water deficit,
calculated as baseline TBW ((Na post/Na pre)1).
MR measurements of kidney volume, cyst volumes, and RBF
MR images were obtained on 1.5-T scanners (Signa; GE Medical
Systems, Milwaukee, WI) at 1100 hours on study day 0 and 8.
After an initial scout to localize the kidneys, coronal T2-weighted
images (single-shot fast spin-echo/fast imaging employing
steady-state acquisition) with 3 and 9mm fixed slice thickness
and three-dimensional volume-interpolated spoiled-gradient
echo coronal T1-weighted images were obtained (5-mm slice
thickness).
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For kidney volume measurements, image data were transferred
digitally to a workstation. The two MRIs for each patient were
examined at the same time, but they were de-identified and the
examiner was blinded to the dates and patient data. Coronal
T2-weighted images were used to outline both kidneys and TKV was
calculated using the ANALYZE bioimaging software system (Mayo
Foundation, Biomedical Imaging Resource, Rochester, MN). On five
arbitrarily selected patients, measurements were carried out on two
separate occasions for later assessment of intraobserver variability.
The interval between the consecutive sets of measurements was at
least 30 days. The average intraobserver variability (or percentage
measurement error) was 0.70%.
For measurements of individual cyst volumes, 11–20 cysts
measuring 16–97mm in diameter, with good quality images on
both, pre- and post-tolvaptan studies were selected. Coronal T2-
weighted images (3mm sections) were used to outline each cyst and
cyst volumes were calculated using the ANALYZE bioimaging
software system. As for TKV, all measurements were blinded to
study dates.
For RBF measurements, thick-section, oblique-axial, two-dimen-
sional, phase-contrast, breath-hold MR angiograms were obtained
along the course of each renal artery and acted as reference images.
The MR flow measurements were obtained perpendicular to the
oblique-axial, two-dimensional reference images of the renal arteries
using a cardiac-gated, two-dimensional, fast gradient-echo, phase-
contrast pulse sequence. MR blood flow pulse sequence parameters
were repetition time¼ 8–10ms, echo time¼ 3–5ms, field of
view¼ 14–20 cm, flip angle¼ 201, 5-mm slice thickness, 224–256
phase encodings, one excitation. The velocity encoding value was
100 cm/s, and flow acquisition was obtained in the slice direction.
Flow analysis was performed using FLOW software version 4
(Medis, Leiden, The Netherlands). Semiautomated or manual
techniques were used for definition of the vessel borders in the
flow images depending on image quality. Vessel area estimations
were made in images at all phases of the cardiac cycle. All RBF
measurements were performed by the same radiologist (JG).
Validation of the technique used in regards to accuracy and
reproducibility have been reported.39–41
Data handling and statistical considerations
No formal sample size calculation was performed. The number of
subjects tested was based on experience from other previous clinical
studies. Only key exploratory analyses are reported in this paper,
pharmacokinetic analyses will be reported elsewhere.
The primary outcome variables were the changes in GFR and
RBF determined by PAH and MR from study day 0 to 8. Secondary
outcomes were changes in urine volume, uric acid, osmolar and free
water clearances, urine protein/creatinine ratio, urine albumin/
creatinine ratio, serum cystatin C concentrations, plasma renin
activity, plasma aldosterone concentrations, and the assessment of
the safety of tolvaptan determined by the presence of adverse event,
vital signs, laboratory tests, and electrocardiograms. Exploratory
assessments included markers of volume status, for example, serum
sodium, serum protein, blood hemoglobin, fluid intake, and thirst
ratings. Changes in TKV and individual cyst volume were assessed
post hoc by raters blinded to image sequence.
The changes in the primary and secondary renal hemodynamic
parameters at study day 8 were tested against study day 0 using
paired t-test. Comparisons between patients with GFRX60ml/min
per 1.73m2 and o60ml/min per 1.73m2 were performed
using unpaired t-test. All tests were two-sided with alpha level
0.05. Pearson’s correlations were performed to determine linear
correlation.
Measurement error was calculated as the absolute value of the
difference between the measured volumes of the same patient at the
two readings. Intraobserver variability, as the percentage measure-
ment error, was determined by dividing the measurement error by
the average of the two measurements for each MR study.
An adverse event was defined as any new medical problem, or
exacerbation of an existing problem, experienced by a subject while
enrolled in the study, whether or not it was considered drug related
by the investigator.
Data are presented as means (±s.d.) or medians (range) when
appropriated. All statistics were performed at Mayo using JMP
software, version 8.0 (SAS Institute, Cary, NC).
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